Hussein Nabil Abdallah  <br/><br/>
Early versus late indomethacin treatment for patent ductus arteriosus in premature infants /  
 المقارنة بين الاستخدام المبكر والمتأخر لعقار الاندوميثاسين لغلق القناة الشريانية فى الأطفال المبتسرين 
Hussein Nabil Abdallah ; Supervised Mohamed Fawzan Shaltout , Mohamed Ahmed Aboulhassan , Alaa Eldin Adel Sobeih 
 - Cairo :   Hussein Nabil Abdallah  ,   2014 
 - 98 P. :   charts , facsimiles ;   25cm 
<br/><br/>Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics 
<br/><br/> Patent ductus arteriosus is a postnatal communication, usually  between the main pulmonary trunk and the descending thoracic aorta.  The clinical consequences of PDA are related to the magnitude of  the left-to-right shunt through the PDA with its associated change in  blood flow to the lung, kidneys, and intestine, leading to tachypnea,  apnea, CO2 retention and increased need to mechanical ventilation.  Indomethacin is the only non-selective cyclooxygenase inhibitor  approved by FDA for the treatment of PDA. It has been clearly  established both by observational studies and randomized trials that  indomethacin increases the rate of PDA closure within 24 hours of its  administration. Less clearly established are the optimal timing, dose, and  duration of treatment 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Arteriosus  Indomethacin   Premature infants